Kristen Kluska
Stock Analyst at Cantor Fitzgerald
(4.58)
# 532
Out of 4,502 analysts
148
Total ratings
47.54%
Success rate
42.25%
Average return
Main Sectors:
Top Industries:
37 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RARE Ultragenyx Pharmaceutical | Reiterates: Overweight | $115 | $45.06 | +155.22% | 10 | Jul 22, 2024 | |
| QURE uniQure | Reiterates: Overweight | $24 | $8.57 | +180.05% | 3 | Jul 16, 2024 | |
| FULC Fulcrum Therapeutics | Reiterates: Overweight | $23 | $8.64 | +166.20% | 2 | Jul 10, 2024 | |
| ADMA ADMA Biologics | Maintains: Overweight | $10 → $15 | $13.08 | +14.68% | 6 | Jul 9, 2024 | |
| HUMA Humacyte | Reiterates: Overweight | $7 | $8.15 | -14.11% | 6 | Jul 2, 2024 | |
| SKYE Skye Bioscience | Reiterates: Overweight | $14 | $5.90 | +137.29% | 4 | Jul 1, 2024 | |
| ETNB 89bio | Reiterates: Overweight | $29 | $9.66 | +200.21% | 11 | Jul 1, 2024 | |
| PTCT PTC Therapeutics | Maintains: Overweight | $52 → $62 | $33.57 | +84.69% | 11 | Jul 1, 2024 | |
| SRPT Sarepta Therapeutics | Reiterates: Neutral | $128 | $147.56 | -13.26% | 10 | Jun 21, 2024 | |
| TSHA Taysha Gene Therapies | Reiterates: Overweight | $7 | $2.27 | +208.37% | 13 | Jun 20, 2024 | |
| CLDX Celldex Therapeutics | Reiterates: Overweight | $67 | $43.86 | +52.76% | 8 | Jun 18, 2024 | |
| MREO Mereo BioPharma Group | Reiterates: Overweight | $7 | $4.08 | +71.57% | 6 | Jun 12, 2024 | |
| XFOR X4 Pharmaceuticals | Reiterates: Overweight | $5 | $0.86 | +478.17% | 3 | May 31, 2024 | |
| CDXS Codexis | Initiates: Overweight | $11 | $3.65 | +201.37% | 1 | May 30, 2024 | |
| IRON Disc Medicine | Reiterates: Overweight | $85 | $43.92 | +93.53% | 5 | May 28, 2024 | |
| ABEO Abeona Therapeutics | Maintains: Overweight | $28 → $21 | $5.03 | +317.50% | 6 | May 16, 2024 | |
| CAPR Capricor Therapeutics | Reiterates: Overweight | $8 | $4.43 | +80.59% | 2 | May 14, 2024 | |
| ATNM Actinium Pharmaceuticals | Reiterates: Overweight | $21 | $7.90 | +165.82% | 3 | Apr 30, 2024 | |
| RIGL Rigel Pharmaceuticals | Maintains: Neutral | $20 → $30 | $10.90 | +175.23% | 4 | Mar 6, 2024 | |
| FOLD Amicus Therapeutics | Reiterates: Overweight | $22 | $10.26 | +114.42% | 4 | Feb 29, 2024 | |
| LCTX Lineage Cell Therapeutics | Reiterates: Overweight | $6 | $1.04 | +476.92% | 3 | Feb 5, 2024 | |
| SLNO Soleno Therapeutics | Maintains: Overweight | $19 → $35 | $46.95 | -25.45% | 3 | Sep 26, 2023 | |
| OTLK Outlook Therapeutics | Downgrades: Neutral | $90 → $20 | $8.34 | +139.81% | 2 | Aug 30, 2023 | |
| DRTS Alpha Tau Medical | Reiterates: Overweight | $23 | $2.13 | +979.81% | 2 | Aug 29, 2023 | |
| MBIO Mustang Bio | Reiterates: Overweight | $18 | $0.35 | +5,090.31% | 1 | Aug 24, 2023 | |
| OCUP Ocuphire Pharma | Reiterates: Overweight | $17 | $2.04 | +733.33% | 3 | Aug 14, 2023 | |
| DRRX DURECT | Maintains: Overweight | $44 → $41 | $1.65 | +2,384.85% | 2 | Aug 10, 2023 | |
| GLTO Galecto | Initiates: Overweight | $16 | $0.56 | +2,756.63% | 1 | Mar 17, 2023 | |
| IBIO iBio, Inc. | Downgrades: Neutral | $1,250 → $85 | $2.22 | +3,728.83% | 3 | Oct 7, 2022 | |
| HEPA Hepion Pharmaceuticals | Initiates: Overweight | $70 | $0.76 | +9,098.42% | 1 | Feb 28, 2022 | |
| EVLO Evelo Biosciences | Initiates: Overweight | n/a | $0.00 | - | 1 | Jun 23, 2021 | |
| CMMB Chemomab Therapeutics | Initiates: Overweight | n/a | $1.19 | - | 1 | May 26, 2021 | |
| OCGN Ocugen | Downgrades: Neutral | n/a | $1.63 | - | 3 | May 7, 2021 | |
| MRKR Marker Therapeutics | Initiates: Overweight | n/a | $5.29 | - | 1 | Mar 19, 2021 | |
| EVGN Evogene | Initiates: Overweight | n/a | $4.84 | - | 1 | Dec 1, 2020 | |
| GLMD Galmed Pharmaceuticals | Assumes: Overweight | n/a | $0.31 | - | 1 | Jan 30, 2020 | |
| PHGE BiomX | Initiates: Overweight | n/a | $0.23 | - | 1 | Jan 9, 2020 |
Ultragenyx Pharmaceutical
Jul 22, 2024
Reiterates: Overweight
Price Target: $115
Current: $45.06
Upside: +155.22%
uniQure
Jul 16, 2024
Reiterates: Overweight
Price Target: $24
Current: $8.57
Upside: +180.05%
Fulcrum Therapeutics
Jul 10, 2024
Reiterates: Overweight
Price Target: $23
Current: $8.64
Upside: +166.20%
ADMA Biologics
Jul 9, 2024
Maintains: Overweight
Price Target: $10 → $15
Current: $13.08
Upside: +14.68%
Humacyte
Jul 2, 2024
Reiterates: Overweight
Price Target: $7
Current: $8.15
Upside: -14.11%
Skye Bioscience
Jul 1, 2024
Reiterates: Overweight
Price Target: $14
Current: $5.90
Upside: +137.29%
89bio
Jul 1, 2024
Reiterates: Overweight
Price Target: $29
Current: $9.66
Upside: +200.21%
PTC Therapeutics
Jul 1, 2024
Maintains: Overweight
Price Target: $52 → $62
Current: $33.57
Upside: +84.69%
Sarepta Therapeutics
Jun 21, 2024
Reiterates: Neutral
Price Target: $128
Current: $147.56
Upside: -13.26%
Taysha Gene Therapies
Jun 20, 2024
Reiterates: Overweight
Price Target: $7
Current: $2.27
Upside: +208.37%
Celldex Therapeutics
Jun 18, 2024
Reiterates: Overweight
Price Target: $67
Current: $43.86
Upside: +52.76%
Mereo BioPharma Group
Jun 12, 2024
Reiterates: Overweight
Price Target: $7
Current: $4.08
Upside: +71.57%
X4 Pharmaceuticals
May 31, 2024
Reiterates: Overweight
Price Target: $5
Current: $0.86
Upside: +478.17%
Codexis
May 30, 2024
Initiates: Overweight
Price Target: $11
Current: $3.65
Upside: +201.37%
Disc Medicine
May 28, 2024
Reiterates: Overweight
Price Target: $85
Current: $43.92
Upside: +93.53%
Abeona Therapeutics
May 16, 2024
Maintains: Overweight
Price Target: $28 → $21
Current: $5.03
Upside: +317.50%
Capricor Therapeutics
May 14, 2024
Reiterates: Overweight
Price Target: $8
Current: $4.43
Upside: +80.59%
Actinium Pharmaceuticals
Apr 30, 2024
Reiterates: Overweight
Price Target: $21
Current: $7.90
Upside: +165.82%
Rigel Pharmaceuticals
Mar 6, 2024
Maintains: Neutral
Price Target: $20 → $30
Current: $10.90
Upside: +175.23%
Amicus Therapeutics
Feb 29, 2024
Reiterates: Overweight
Price Target: $22
Current: $10.26
Upside: +114.42%
Lineage Cell Therapeutics
Feb 5, 2024
Reiterates: Overweight
Price Target: $6
Current: $1.04
Upside: +476.92%
Soleno Therapeutics
Sep 26, 2023
Maintains: Overweight
Price Target: $19 → $35
Current: $46.95
Upside: -25.45%
Outlook Therapeutics
Aug 30, 2023
Downgrades: Neutral
Price Target: $90 → $20
Current: $8.34
Upside: +139.81%
Alpha Tau Medical
Aug 29, 2023
Reiterates: Overweight
Price Target: $23
Current: $2.13
Upside: +979.81%
Mustang Bio
Aug 24, 2023
Reiterates: Overweight
Price Target: $18
Current: $0.35
Upside: +5,090.31%
Ocuphire Pharma
Aug 14, 2023
Reiterates: Overweight
Price Target: $17
Current: $2.04
Upside: +733.33%
DURECT
Aug 10, 2023
Maintains: Overweight
Price Target: $44 → $41
Current: $1.65
Upside: +2,384.85%
Galecto
Mar 17, 2023
Initiates: Overweight
Price Target: $16
Current: $0.56
Upside: +2,756.63%
iBio, Inc.
Oct 7, 2022
Downgrades: Neutral
Price Target: $1,250 → $85
Current: $2.22
Upside: +3,728.83%
Hepion Pharmaceuticals
Feb 28, 2022
Initiates: Overweight
Price Target: $70
Current: $0.76
Upside: +9,098.42%
Evelo Biosciences
Jun 23, 2021
Initiates: Overweight
Price Target: n/a
Current: $0.00
Upside: -
Chemomab Therapeutics
May 26, 2021
Initiates: Overweight
Price Target: n/a
Current: $1.19
Upside: -
Ocugen
May 7, 2021
Downgrades: Neutral
Price Target: n/a
Current: $1.63
Upside: -
Marker Therapeutics
Mar 19, 2021
Initiates: Overweight
Price Target: n/a
Current: $5.29
Upside: -
Evogene
Dec 1, 2020
Initiates: Overweight
Price Target: n/a
Current: $4.84
Upside: -
Galmed Pharmaceuticals
Jan 30, 2020
Assumes: Overweight
Price Target: n/a
Current: $0.31
Upside: -
BiomX
Jan 9, 2020
Initiates: Overweight
Price Target: n/a
Current: $0.23
Upside: -